P2Y inhibition by clopidogrel increases adverse clinical events after transcatheter aortic valve replacement.

Date publication

mai 2022

Journal

International journal of cardiology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr OHANA Mickaël

Tous les auteurs :
Matsushita K, Marchandot B, Kibler M, Heger J, Peillex M, Trimaille A, Hess S, Grunebaum L, Ohana M, Reydel A, Jesel L, Ohlmann P, Morel O

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35525324

Résumé

Dual antiplatelet therapy (DAPT) has been proposed to explain the increased occurrence of bleeding events after transcatheter aortic valve replacement (TAVR) despite no relevant study exploring the extent of platelet inhibition. In the present study, we sought to assess whether P2Y inhibition by clopidogrel impacts clinical outcomes in TAVR patients.

Mots clés

Antiplatelet therapy, Bleeding, Transcatheter aortic valve replacement

Référence

Int J Cardiol. 2022 May 4;: